Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin

Molecular and Cellular Endocrinology

Volumn 431, Issue , 2016, Pages 12-23

  Sharma, Vikas ^a   Kumar, Lokesh ^a   Mohanty, Sujit K ^a   Maikhuri, Jagdamba P ^a   Rajender, Singh ^a   Gupta, Gopal ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Androgen receptor; Curcumin; DNA methylation; Prostate cancer; Quercetin

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; BISULFITE; CASPASE 3; CURCUMIN; DNA METHYLTRANSFERASE; LUCIFERASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; QUERCETIN; SMALL INTERFERING RNA; ANDROGEN; AR PROTEIN, HUMAN;

APOPTOSIS; AR GENE; ARTICLE; CANCER INHIBITION; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG POTENTIATION; DU145 CELL LINE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MALE; PC3 CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; CELL LINE; DRUG EFFECTS; EPIGENETIC REPRESSION; GENETICS; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANDROGENS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DIHYDROTESTOSTERONE; DNA METHYLATION; DOWN-REGULATION; DRUG SYNERGISM; EPIGENETIC REPRESSION; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; QUERCETIN; RECEPTORS, ANDROGEN; RNA, MESSENGER;

EID: 84964969318     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.04.024     Document Type: Article

References (44)

1. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23:363-398.
2. Albany C., Alva A.S., Aparicio A.M., Singal R., Yellapragada S., Sonpavde G., Hahn N.M. Epigenetics in prostate cancer. Prostate Cancer 2011, 580318. Epub 2011 Nov 30. 10.1155/2011/580318.
3. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324-326.
4. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
5. Chlenski A., Nakashiro K., Ketels K.V., Korovaitseva G.I., Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001, 47:66-75.
6. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.
7. Elattar T.M., Virji A.S. The effect of red wine and its components on growth and proliferation of human oral squamous carcinoma cells. Anticancer Res. 1999, 19:5407-5414.
8. Espinosa A.M., Alfaro A., Roman-Basaure E., Guardado-Estrada M., Palma I., Serralde C., Medina I., Juarez E., Bermudez M., Marquez E., Borges-Ibanez M., Munoz-Cortez S., Alcantara-Vazquez A., Alonso P., Curiel-Valdez J., Kofman S., Villegas N., Berumen J. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One 2013, 8:e55975.
9. Festuccia C., Gravina G.L., D'Alessandro A.M., Muzi P., Millimaggi D., Dolo V., Ricevuto E., Vicentini C., Bologna M. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr. Relat. Cancer 2009, 16:401-413.
10. Fluchter S.H., Weiser R., Gamper C. The role of hormonal treatment in prostate cancer. Recent Results Cancer Res. 2007, 175:211-237.
11. Gore S.D. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol. 2005, 2(Suppl. 1):S30-S35.
12. Gravina G.L., Marampon F., Di S.M., Bonfili P., Vitturini A., Jannini E.A., Pestell R.G., Tombolini V., Festuccia C. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 2010, 70:1166-1178.
13. Harwood M., Danielewska-Nikiel B., Borzelleca J.F., Flamm G.W., Williams G.M., Lines T.C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 2007, 45:2179-2205.
14. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25:276-308.
15. Hisatake J.I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H.P. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res. 2000, 60:5494-5498.
16. Hutchins-Wolfbrandt A., Mistry A.M. Dietary turmeric potentially reduces the risk of cancer. Asian Pac. J. Cancer Prev. 2011, 12:3169-3173.
17. Jarrard D.F., Kinoshita H., Shi Y., Sandefur C., Hoff D., Meisner L.F., Chang C., Herman J.G., Isaacs W.B., Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 1998, 58:5310-5314.
18. Krycer J.R., Brown A.J. Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?. PLoS One 2013, 8:e54007.
19. Kumar R., Verma V., Jain A., Jain R.K., Maikhuri J.P., Gupta G. Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. J. Nutr. Biochem. 2011, 22:723-731.
20. Lee W.J., Shim J.Y., Zhu B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 2005, 68:1018-1030.
21. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2013, 332:304-312.
22. Liu Z., Xie Z., Jones W., Pavlovicz R.E., Liu S., Yu J., Li P.K., Lin J., Fuchs J.R., Marcucci G., Li C., Chan K.K. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 2009, 19:706-709.
23. Lu W.J., Lee N.P., Kaul S.C., Lan F., Poon R.T., Wadhwa R., Luk J.M. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death. Differ. 2011, 18:1046-1056.
24. Medina-Franco J.L., Lopez-Vallejo F., Kuck D., Lyko F. Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol. Divers. 2011, 15:293-304.
25. Mitchell S., Abel P., Ware M., Stamp G., Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int. 2000, 85:932-944.
26. Miyamoto H., Messing E.M., Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?. Nat. Clin. Pract. Oncol. 2005, 2:236-237.
27. Nair P., Malhotra A., Dhawan D.K. Curcumin and quercetin trigger apoptosis during benzo(a)pyrene-induced lung carcinogenesis. Mol. Cell. Biochem. 2015, 400:51-56.
28. Nakayama T., Watanabe M., Suzuki H., Toyota M., Sekita N., Hirokawa Y., Mizokami A., Ito H., Yatani R., Shiraishi T. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Investig. 2000, 80:1789-1796.
29. Niu Y., Altuwaijri S., Lai K.P., Wu C.T., Ricke W.A., Messing E.M., Yao J., Yeh S., Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12182-12187.
30. Niu Y., Chang T.M., Yeh S., Ma W.L., Wang Y.Z., Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010, 29:3593-3604.
31. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60:6039-6044.
32. Priyadarsini R.V., Vinothini G., Murugan R.S., Manikandan P., Nagini S. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr. Cancer 2011, 63:218-226.
33. Richter M., Ebermann R., Marian B. Quercetin-induced apoptosis in colorectal tumor cells: possible role of EGF receptor signaling. Nutr. Cancer 1999, 34:88-99.
34. Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Chavez-Blanco A., Revilla-Vazquez A., Benitez-Bribiesca L., Duenas-Gonzalez A. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J. Transl. Med. 2006, 4:32.
35. Shen W., Chang A., Wang J., Zhou W., Gao R., Li J., Xu Y., Luo X., Xiang R., Luo N., Stupack D.G. TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer. Oncogenesis 2015, 4:e173. 10.1038/oncsis.2015.30.
36. Tang S.N., Fu J., Shankar S., Srivastava R.K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One 2012, 7:e31067.
37. Teiten M.H., Eifes S., Dicato M., Diederich M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2010, 2:128-162.
38. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57:205-225.
39. Wainfan E., Poirier L.A. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 1992, 52:2071s-2077s.
40. Wang X., Deng H., Basu I., Zhu L. Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein. Cancer Res. 2004, 64:1377-1385.
41. Weisberg E., Ray A., Nelson E., Adamia S., Barrett R., Sattler M., Zhang C., Daley J.F., Frank D., Fox E., Griffin J.D. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One 2011, 6:e25351.
42. Wen S., Niu Y., Lee S.O., Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat. Rev. 2014, 40:31-40.
43. Zhang J.Y., Lin M.T., Zhou M.J., Yi T., Tang Y.N., Tang S.L., Yang Z.J., Zhao Z.Z., Chen H.B. Combinational treatment of curcumin and quercetin against gastric cancer MGC-803 cells in vitro. Molecules 2015, 20:11524-11534.
44. Zhu H., Zhang L., Wu S., Teraishi F., Davis J.J., Jacob D., Fang B. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK. Oncogene 2004, 23:4984-4992.